09:21 AM EST, 11/07/2025 (MT Newswires) -- Health care stocks were mixed premarket Friday, with the Health Care Select Sector SPDR Fund ( XLV ) marginally higher and the iShares Biotechnology ETF (IBB) declining by 0.3%.

Rhythm Pharmaceuticals ( RYTM ) stock was down more than 3% after the company said the US Food and Drug Administration extended the review period for its supplemental new drug application for Imcivree, or setmelanotide, for treating acquired hypothalamic obesity by three months to March 20, 2026, from Dec. 20.

Gilead Sciences ( GILD ) shares were up more than 1% after the company said new long-term data on its drug Livdelzi showed consistent efficacy and safety in treating primary biliary cholangitis, including in patients who switched from obeticholic acid, with sustained improvements in liver stiffness over three years.

Claritev ( CTEV ) stock was up nearly 13% after the company reported a narrower Q3 net loss amid higher revenue, and raised its 2025 revenue growth outlook.